Concurrent miR-21 suppression and FXR activation as a mechanism of improvement in nonalcoholic fatty liver disease.
作者信息
Mazzini Guilherme S, Khoraki Jad, Browning Matthew G, Campos Guilherme M
机构信息
Department of Gastrointestinal Surgery, Hospital de Clinicas de Porto Alegre, 2350 Ramiro Bracelos Street, Porto Alegre, RS, Brazil.
Department of Surgery, Virginia Commonwealth University, 1200 East Broad Street, Richmond, VA, USA.
出版信息
Cell Death Dis. 2018 Mar 2;9(3):354. doi: 10.1038/s41419-018-0386-3.
Abstract
摘要
相似文献
1
Concurrent miR-21 suppression and FXR activation as a mechanism of improvement in nonalcoholic fatty liver disease.同时抑制miR-21和激活FXR作为改善非酒精性脂肪性肝病的一种机制。
Cell Death Dis. 2018 Mar 2;9(3):354. doi: 10.1038/s41419-018-0386-3.
2
Use of farnesoid X receptor agonists to treat nonalcoholic fatty liver disease.使用法尼醇X受体激动剂治疗非酒精性脂肪性肝病。
Dig Dis. 2015;33(3):426-32. doi: 10.1159/000371698. Epub 2015 May 27.
3
MicroRNA-194 inhibition improves dietary-induced non-alcoholic fatty liver disease in mice through targeting on FXR.miR-194 抑制通过靶向 FXR 改善饮食诱导的小鼠非酒精性脂肪性肝病。
Biochim Biophys Acta Mol Basis Dis. 2017 Dec;1863(12):3087-3094. doi: 10.1016/j.bbadis.2017.09.020. Epub 2017 Sep 22.
4
Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis.法尼醇 X 受体靶向治疗非酒精性脂肪性肝炎。
Drug Discov Today. 2012 Sep;17(17-18):988-97. doi: 10.1016/j.drudis.2012.05.012. Epub 2012 May 29.
5
Obeticholic acid for the treatment of nonalcoholic steatohepatitis: Expectations and concerns.用于治疗非酒精性脂肪性肝炎的奥贝胆酸：期望与担忧。
Metabolism. 2020 Mar;104:154144. doi: 10.1016/j.metabol.2020.154144. Epub 2020 Jan 11.
6
Gene expression profiling in human precision cut liver slices in response to the FXR agonist obeticholic acid.人精准切肝片中受 FXR 激动剂奥贝胆酸刺激的基因表达谱
J Hepatol. 2016 May;64(5):1158-1166. doi: 10.1016/j.jhep.2016.01.016. Epub 2016 Jan 23.
7
Effects of Farnesoid X Receptor Activation on Arachidonic Acid Metabolism, NF-kB Signaling, and Hepatic Inflammation.法尼醇 X 受体激活对花生四烯酸代谢、NF-κB 信号通路和肝脏炎症的影响。
Mol Pharmacol. 2018 Aug;94(2):802-811. doi: 10.1124/mol.117.111047. Epub 2018 May 9.
8
Is obeticholic Acid the solution to nonalcoholic steatohepatitis?奥贝胆酸是治疗非酒精性脂肪性肝炎的解决方案吗？
Gastroenterology. 2015 Apr;148(4):851-2. doi: 10.1053/j.gastro.2015.02.044. Epub 2015 Feb 26.
9
Obeticholic acid and resveratrol in nonalcoholic fatty liver disease: all that is gold does not glitter, not all those who wander are lost.非酒精性脂肪性肝病中的奥贝胆酸和白藜芦醇：闪光的不一定都是金子，徘徊的人不一定都迷失。
Hepatology. 2015 Jun;61(6):2104-6. doi: 10.1002/hep.27772. Epub 2015 Apr 8.
10
MicroRNA-122 Inhibits Lipid Droplet Formation and Hepatic Triglyceride Accumulation via Yin Yang 1.微小RNA-122通过阴阳1抑制脂滴形成和肝脏甘油三酯蓄积。
Cell Physiol Biochem. 2017;44(4):1651-1664. doi: 10.1159/000485765. Epub 2017 Dec 6.
引用本文的文献
1
Facile Splint-Free Circularization of ssDNA with T4 DNA Ligase by Redesigning the Linear Substrate to Form an Intramolecular Dynamic Nick.通过重新设计线性底物形成分子内动态切口，用 T4 DNA 连接酶实现 ssDNA 的简易无夹套环化。
Biomolecules. 2024 Aug 18;14(8):1027. doi: 10.3390/biom14081027.
2
Ursodeoxycholic Acid Modulates the Interaction of miR-21 and Farnesoid X Receptor and NF-κB Signaling.熊去氧胆酸调节miR-21与法尼酯X受体及NF-κB信号通路的相互作用。
Biomedicines. 2024 Jun 2;12(6):1236. doi: 10.3390/biomedicines12061236.
3
Nonalcoholic Fatty Liver Disease (NAFLD): Pathogenesis and Noninvasive Diagnosis.非酒精性脂肪性肝病（NAFLD）：发病机制与非侵入性诊断
Biomedicines. 2021 Dec 22;10(1):15. doi: 10.3390/biomedicines10010015.
4
MicroRNAs in the Pathogenesis of Nonalcoholic Fatty Liver Disease.微小 RNA 在非酒精性脂肪性肝病发病机制中的作用。
Int J Biol Sci. 2021 Apr 29;17(7):1851-1863. doi: 10.7150/ijbs.59588. eCollection 2021.
5
MicroRNA-21 Plays Multiple Oncometabolic Roles in the Process of NAFLD-Related Hepatocellular Carcinoma via PI3K/AKT, TGF-β, and STAT3 Signaling.微小RNA-21通过PI3K/AKT、TGF-β和STAT3信号通路在非酒精性脂肪性肝病相关肝细胞癌发生过程中发挥多种肿瘤代谢作用。
Cancers (Basel). 2021 Feb 24;13(5):940. doi: 10.3390/cancers13050940.
6
Concomitant PPARα and FXR Activation as a Putative Mechanism of NASH Improvement after Gastric Bypass Surgery: a GEO Datasets Analysis.胃旁路手术后非酒精性脂肪性肝炎改善的潜在机制：PPARα 和 FXR 同时激活：一项 GEO 数据集分析。
J Gastrointest Surg. 2019 Jan;23(1):51-57. doi: 10.1007/s11605-018-3938-z. Epub 2018 Sep 11.
7
Modulation of liver steatosis by miR-21/PPAR.miR-21/PPAR对肝脂肪变性的调节作用
Cell Death Discov. 2018 Jul 10;4:9. doi: 10.1038/s41420-018-0076-z. eCollection 2018.
本文引用的文献
1
Anti-obesogenic effects of WY14643 (PPAR-alpha agonist): Hepatic mitochondrial enhancement and suppressed lipogenic pathway in diet-induced obese mice.WY14643（过氧化物酶体增殖物激活受体α激动剂）的抗肥胖作用：饮食诱导的肥胖小鼠肝脏线粒体增强及脂肪生成途径受抑制
Biochimie. 2017 Sep;140:106-116. doi: 10.1016/j.biochi.2017.07.003. Epub 2017 Jul 12.
2
Targeting nuclear receptors for the treatment of fatty liver disease.针对核受体治疗脂肪肝。
Pharmacol Ther. 2017 Nov;179:142-157. doi: 10.1016/j.pharmthera.2017.05.011. Epub 2017 May 23.
3
miR-21 ablation and obeticholic acid ameliorate nonalcoholic steatohepatitis in mice.miR-21缺失与奥贝胆酸改善小鼠非酒精性脂肪性肝炎
Cell Death Dis. 2017 Apr 13;8(4):e2748. doi: 10.1038/cddis.2017.172.
4
Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19·2 million participants.1975年至2014年200个国家成人身体质量指数的趋势：对1698项基于人群测量研究的汇总分析，涉及1920万参与者。
Lancet. 2016 Apr 2;387(10026):1377-1396. doi: 10.1016/S0140-6736(16)30054-X.
5
Liver microRNA-21 is overexpressed in non-alcoholic steatohepatitis and contributes to the disease in experimental models by inhibiting PPARα expression.肝脏微小RNA-21在非酒精性脂肪性肝炎中过度表达，并通过抑制过氧化物酶体增殖物激活受体α（PPARα）的表达在实验模型中导致该疾病。
Gut. 2016 Nov;65(11):1882-1894. doi: 10.1136/gutjnl-2014-308883. Epub 2015 Sep 3.
6
PPARα gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis.PPARα 基因表达与非酒精性脂肪性肝炎患者的严重程度和组织学治疗反应相关。
J Hepatol. 2015 Jul;63(1):164-73. doi: 10.1016/j.jhep.2015.02.019. Epub 2015 Feb 19.
7
Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease.过氧化物酶体增殖物激活受体 α（PPARα）作用的分子机制及其对非酒精性脂肪性肝病中脂质代谢、炎症和纤维化的影响。
J Hepatol. 2015 Mar;62(3):720-33. doi: 10.1016/j.jhep.2014.10.039. Epub 2014 Nov 1.
8
Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression.非酒精性脂肪性肝炎与肝脏微小RNA表达改变有关。
Hepatology. 2008 Dec;48(6):1810-20. doi: 10.1002/hep.22569.
Zotero 插件